Drug interactions
Fosamprenavir + Liposomal doxorubicin
Severity: Moderate
Fosamprenavir and Liposomal doxorubicin: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Amprenavir, the active metabolite of fosamprenavir, inhibits CYP3A4 and may raise doxorubicin exposure. This may increase myelosuppression and cardiac toxicity.
What this interaction means in plain words
Fosamprenavir and Liposomal doxorubicin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Amprenavir inhibits CYP3A4, reducing doxorubicin metabolism.
What to do
Monitor blood counts and cardiac function, and consider doxorubicin dose reduction if toxicity occurs.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Fosamprenavir and Liposomal doxorubicin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Liposomal doxorubicin
- Dengue vaccine + Liposomal doxorubicin Contraindicated
- Belatacept + Liposomal doxorubicin Major
- Cyclosporine + Liposomal doxorubicin Major
- Dronedarone + Liposomal doxorubicin Major
- Elvitegravir / cobicistat / emtricitabine / tenofovir df + Liposomal doxorubicin Major
- Fingolimod + Liposomal doxorubicin Major
Frequently asked questions
Can I take Fosamprenavir with Liposomal doxorubicin?
MediHelp rates the interaction as moderate. Fosamprenavir and Liposomal doxorubicin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Amprenavir, the active metabolite of fosamprenavir, inhibits CYP3A4 and may raise doxorubicin exposure. This may increase myelosuppression and cardiac toxicity.
How serious is the interaction between Fosamprenavir and Liposomal doxorubicin?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood counts and cardiac function, and consider doxorubicin dose reduction if toxicity occurs.
What other medicines interact with Liposomal doxorubicin?
MediHelp also lists interactions of Liposomal doxorubicin with, for example, Dengue vaccine, Belatacept, Cyclosporine. The full list is on the Liposomal doxorubicin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
